We use cookies on accura.dk

accura.dk uses cookies to improve the user-friendliness and functionality. By using our website, you consent to our use of cookies. Read more about cookies at accura.dk. Enjoy.

Read more about our cookie policy and instructions to delete cookies

;

Fertin Pharma A/S acquires Medcan Pharma A/S and Tab Labs Inc.


Caseinfo

The Danish nicotine chewing gum manufacturer Fertin Pharma A/S, whose majority shareholder is the private equity fund EQT, has acquired two companies located in Denmark and Canada.

The company located in Denmark, Medcan Pharma A/S, develops cannabis for medicinal use. The global market for pharmaceutical and medicinal use of cannabis is a growing market. The intention is that Fertin Pharma A/S's knowledge of oral administration of active pharmaceutical ingredients, e.g. in the form of chewing gum, combined with Medcan Pharma A/S's knowledge of the use of cannabinoids will prepare the companies for taking part in such growth.

Fertin Pharma A/S has also acquired the Canadian company Tab Labs Inc. that manufactures chewing gum, mints and lozenges at its headquarters in Vancouver, Canada. The acquisition will serve as Fertin Pharma A/S's way into the North American market where legalisation of cannabinoid-containing products is spreading, and which is estimated to reach a value of more than USD 1bn in 2023.

Thomas Weincke, Morten Bruus, Kim Toftgaard, Jacob Nygaard and Alan Pai advised Fertin Pharma A/S in both transactions.


Contact

Thomas Weincke
Thomas Weincke

Partner, Attorney-at-Law

Mobile: +45 3078 6678
thomas.weincke@accura.dk

Morten Bruus
Morten Bruus

Partner, Attorney-at-Law

Mobile: +45 3078 6695
morten.bruus@accura.dk


Accura's recent cases

We advise in connection with the largest and most complex transactions on the market.

Read a selection of our cases here.

Accura's recent cases

Accura's M&A Team

Accura's M&A Team